Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Funding will support research on conditions including fatty liver disease, liver cancer, asthma and chronic kidney disease.
A research team believes fragmentomics has several advantages when it comes to liquid biopsies for cancer detection.
Genomic profiling showed patients with African ancestry had fewer actionable mutations and were less likely to qualify for immunotherapy.
Including people in Africa and with African ancestry in studies on inherited genetics to address disparities in prostate cancer outcomes.
A small group of adults in remission had persisting mutations that predicted their risk of death from having the cancer return.
The team has reviewed test results for more than 2,700 patients to date.
In the near future, it may be possible to design specific diets tailored to individual genomic profiles to starve tumors.
Assay can also help identify patients who may benefit from ovarian suppression therapy.
Study clarifies molecular pathways by which CLL transform into a more aggressive type of lymphoma.
Krazati led to tumor shrinkage in 43% of previously treated NSCLC patients with KRAS G12C mutations.
Genomic testing is an important tool to guide treatment decisions among women with early-stage breast cancer.
It’s important to know how aggressive a patient’s cancer is so that their treatment can be tailored.
The clinical significance of many of the inherited mutations that can now be identified remains unclear.
A new approach to prognosis looks to patients’ genomes for clues about how their cancer will behave.
Genomic tumor profiling in pediatric patients can clarify diagnosis and treatment, a recent study found.
In a small trial, Jemperli led to complete remission in people with a biomarker for deficient DNA repair.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.